Gene-editing specialist Editas Medicine has halted development of its lead clinical programme for congenital eye disorders after it generated lacklustre results in a phase 1/2 trial. The ...

including generic versions of products like Merz' multiple sclerosis therapy Ampyra (dalfampridine), Novartis' cancer drug Gleevec (imatinib), and Amgen's Sensipar (cinacalcet) for ...

Perspectives you won’t find in the U.S. media. Our leading network of international correspondents and expert reporters in Switzerland provide incisive analyses and deep insight into geopolitics ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

NMPA’s Center for Drug Evaluation accepted Merck KGaA’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with TGCTs that require systemic ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.